A Phase 3 interventional study of Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg and telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg in Hypertension, sponsored by George Medicines PTY Limited. Completed at 89 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-03.
Sponsored by George Medicines PTY Limited · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.
Among the 99 studies testing telmisartan in Hypertension, this one is the 6th largest by enrollment, is one of 3 that started in 2021, is one of 40 in phase 3, and was the 89th registered.
6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.
Browse Hypertension studies →1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:
Chong Kun Dang Pharmaceutical · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 5 · Phase 3 40 · Phase 4 32
First in 1997; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,385 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 184 across the 99 interventional studies. Of the 91 that completed or were terminated, 14 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 99 have an industry lead sponsor. The 10 most frequent:
George Medicines PTY Limited is the lead sponsor of 3 studies on the registry; none are open to participants now.
George Medicines PTY Limited has 2 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 99 studies testing telmisartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Recent hypertension guidelines recommend combination therapy as initial treatment for many or most patients. Several trials suggest triple low-dose combination therapy may be highly effective in terms of achieving blood pressure (BP) control without increasing adverse effects. This trial is designed to investigate the efficacy and safety of GMRx2 in participants with high blood pressure compared to dual combinations.
TRIAL DRUG:
GMRx2: Single pill combinations of telmisartan/amlodipine/indapamide Dose version 2: telmisartan 20mg/amlodipine 2.5mg/indapamide 1.25mg Dose version 3: telmisartan 40mg/amlodipine 5 mg/indapamide 2.5mg INDICATION: Hypertension TRIAL DESIGN: International, multicenter, randomized, double-blind, active controlled, parallel-group.
OBJECTIVES: To investigate the efficacy and safety of GMRx2 compared to dual combinations
INTERVENTION:
Single-Blind Active Run-In Period. Enrolled participants will be asked to discontinue their current BP-lowering drug(s) and undergo a single-blind active run-in period for 4 weeks with GMRx2 dose version 2. Participants will be advised to take the capsule once daily in the morning at approximately the same time each day. For days on which BP is being measured, the capsule should be taken directly after the morning home BP measurement.
Double-Blind Treatment Period. Participants still eligible after the run-in period will be allocated in a double-blind fashion to one of the following 4 randomized groups: GMRx2 dose version 2, or telmisartan 20mg+amlodipine2.5mg, or telmisartan 20mg+indapamide 1.25mg, or amlodipine 2.5mg+indapamide 1.25mg. At week 6 all doses will be doubled.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At screening visit
140-179 mmHg on 0 BP-lowering drugs, or 130-170 mmHg on 1 BP-lowering drug, or 120-160 mmHg on 2 BP-lowering drugs, or 110-150 mmHg on 3 BP-lowering drugs.
At randomization visit
Exclusion Criteria:
At screening visit
At randomization visit
Any of the following which in the investigator's judgment may compromise the safety of the participant if randomized to the trial medications:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg
Drug: Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg · Drug: telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg
Telmisartan 20 mg/amlodipine 2.5 mg . At week 6 visit, forced up-titration to telmisartan 40 mg/amlodipine 5 mg
Drug: Telmisartan 20 mg/amlodipine 2.5 mg · Drug: telmisartan 40 mg/amlodipine 5 mg
Telmisartan 20 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to telmisartan 40 mg/indapamide 2.5 mg
Drug: Telmisartan 20 mg/indapamide 1.25 mg · Drug: telmisartan 40 mg/indapamide 2.5 mg
Amlodipine 2.5 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to amlodipine 5 mg/indapamide 2.5 mg
Drug: Amlodipine 2.5 mg/indapamide 1.25 mg · Drug: amlodipine 5 mg/indapamide 2.5 mg
Drug page: Telmisartan
Single pill
Drug page: Telmisartan
Single pill
Drug page: Telmisartan
oral tablet
Drug page: Telmisartan
oral tablet
Drug page: Telmisartan
oral tablet
Drug page: Telmisartan
oral tablet
Drug page: Amlodipine
oral tablet
Drug page: Amlodipine
oral tablet
Difference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 12
The primary outcome measure is difference in change in average home SBP for GMRx2 vs each dual combination evaluated from randomization to Week 12. The change in home SBP from randomization for all treatment arms was measured using least squares (LS) mean change. The pairwise comparisons between GMRx2 and dual treatments in change in home SBP were estimated using LS means difference and are described in the statistical analysis.
Time frame: Week 12
Difference in Change in Clinic Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 12
Difference in change in average clinic SBP for GMRx2 vs each dual combination was evaluated from randomization to Week 12.
Time frame: Week 12
Difference in Change in Clinic Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 6
Difference in change in average clinic SBP for GMRx2 vs each dual combination was evaluated from randomization to Week 6.
Time frame: Week 6
Difference in Change in Clinic Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 12
Difference in change in average clinic DBP for GMRx2 vs each dual combination was evaluated from randomization to Week 12.
Time frame: Week 12
Difference in Change in Clinic Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 6
Difference in change in average clinic DBP for GMRx2 vs each dual combination was evaluated from randomization to Week 6.
Time frame: Week 6
Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <140 and Diastolic Blood Pressure (DBP) <90 mmHg at Week 12
The percentage of participants achieving averaged clinic SBP \<140 mmHg and DBP \<90 mmHg at Week 12 was evaluated.
Time frame: Week 12
Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <140 and Diastolic Blood Pressure (DBP) <90 mmHg at Week 6
The percentage of participants achieving averaged clinic SBP \<140 mmHg and DBP \<80 mmHg at Week 6 was evaluated.
Time frame: Week 6
Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 12
The percentage of participants achieving averaged clinic SBP \<130 mmHg and DBP \<80 mmHg at Week 12 was evaluated.
Time frame: Week 12
Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 6
The percentage of participants achieving averaged clinic SBP \<130 mmHg and DBP \<80 mmHg at Week 6 was evaluated.
Time frame: Week 6
Difference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 6
Difference in change in average home SBP for GMRx2 vs each dual combination was evaluated from randomization to Week 6.
Time frame: Week 6
Difference in Change in Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 12
Difference in change in average home DBP for GMRx2 vs each dual combination was evaluated from randomization to Week 12.
Time frame: Week 12
Difference in Change in Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 6
Difference in change in average home DBP for GMRx2 vs each dual combination was evaluated from randomization to Week 6.
Time frame: Week 6
Difference in Change in Trough Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 12
Difference in change in trough home SBP for GMRx2 vs each dual combination was evaluated from randomization to Week 12. Trough values were measured before morning dose of the study medication.
Time frame: Week 12
Difference in Change in Trough Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 6
Difference in change in trough home SBP for GMRx2 vs each dual combination was evaluated from randomization to Week 6. Trough values were measured before morning dose of the study medication.
Time frame: Week 6
Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <135 and Diastolic Blood Pressure (DBP) <85 mmHg at Week 12
The percentage of participants achieving averaged home SBP \<135 mmHg and DBP \<85 mmHg at week 12 was calculated.
Time frame: Week 12
Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <135 and Diastolic Blood Pressure (DBP) <85 mmHg at Week 6
The percentage of participants achieving averaged home SBP \<135 mmHg and DBP \<85 mmHg at Week 6 was evaluated.
Time frame: Week 6
Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 12
The percentage of participants achieving averaged home SBP \<130 mmHg and DBP \<80 mmHg at Week 12 was evaluated.
Time frame: Week 12
Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 6
The percentage of participants achieving averaged home SBP \<130 mmHg and DBP \<80 mmHg at Week 6 was evaluated.
Time frame: Week 6
Percentage of Participants Discontinued Trial Medication Due to Adverse Event (AE)/Serious Adverse Event (SAE) From Randomization to Week 12
The primary safety outcome is the proportion of participants who discontinued trial medication due to an AE or SAE from randomization to follow-up at Week 12.
Time frame: Week 12
Percentage of Participants Discontinued Trial Medication Due to Adverse Event (AE)/Serious Adverse Event (SAE) From Randomization to Week 6
The secondary safety outcome is the proportion of participants who discontinued trial medication due to AE/SAE from randomization to follow-up at Week 6.
Time frame: Week 6
Percentage of Participants With a Serious Adverse Event (SAE) From Randomization to Week 12
The secondary safety outcome is the proportion of participants with at least one SAE from randomization to follow-up at Week 12.
Time frame: At Week 12
Percentage of Participants With Serious Adverse Event (SAE) From Randomization to Week 6
The secondary safety outcome is the proportion of participants with at least one SAE from randomization to follow-up at Week 6.
Time frame: Week 6
Percentage of Participants With Symptomatic Hypotension From Randomization to Week 12
The secondary safety outcome is the proportion of participants who experienced at least one symptomatic hypotension episode from randomization to follow-up at Week 12.
Time frame: Week 12
Percentage of Participants With Symptomatic Hypotension From Randomization to Week 6
The secondary safety outcome is the proportion of participants who experienced at least one symptomatic hypotension episode from randomization to follow-up at Week 6.
Time frame: Week 6
Percentage of Participants With Serum Sodium Concentration Below 135 mmol/l at Week 12
The secondary safety outcome is the proportion of participants with serum sodium \<135 mmol/L at follow-up Week 12.
Time frame: Week 12
Percentage of Participants With Serum Sodium Concentration Below 135 mmol/l at Week 6
The secondary safety outcome is the proportion of participants with serum sodium \<135 mmol/L at follow-up Week 6.
Time frame: Week 6
Percentage of Participants With Serum Sodium Concentration Above 145 mmol/l at Week 12
The secondary safety outcome is the proportion of participants with serum sodium \>145 mmol/L at follow-up Week 12.
Time frame: Week 12
Percentage of Participants With Serum Sodium Concentration Above 145 mmol/l at Week 6
The secondary safety outcome is the proportion of participants with serum sodium \>145 mmol/L at follow-up Week 6.
Time frame: Week 6
Percentage of Participants With Serum Potassium Concentration Below 3.5 mmol/l at Week 12
The secondary safety outcome is the proportion of participants with serum potassium concentration \<3.5 mmol/L at follow-up Week 12.
Time frame: Week 12
Percentage of Participants With Serum Potassium Concentration Below 3.5 mmol/l at Week 6
The secondary safety outcome is the proportion of participants with serum potassium concentration below 3.5 mmol/l at follow-up Week 6.
Time frame: Week 6
Percentage of Participants With Serum Potassium Concentration Above 5.5 mmol/l at Week 12
The secondary safety outcome is proportion of participants with serum potassium concentration \>5.5 mmol/l at follow-up Week 12.
Time frame: Week 12
Percentage of Participants With Serum Potassium Concentration Above 5.5 mmol/l at Week 6
The secondary safety outcome is proportion of participants with serum potassium concentration \>5.5 mmol/L at follow-up Week 6.
Time frame: Week 6
Percentage of Participants With Estimated Glomerular Filtration Rate (eGFR) Drop of Over 30% From Randomization to Week 12
The secondary safety outcome was the proportion of participants with an eGFR drop of over 30% from randomization to follow-up at Week 12.
Time frame: Week 12
Percentage of Participants With Estimated Glomerular Filtration Rate (eGFR) Drop of Over 30% From Randomization to Week 6
The secondary safety outcome is the proportion of participants with an eGFR drop of over 30% from randomization to follow-up at Week 6.
Time frame: Week 6
Percentage of Participants With Serum Sodium <135mmol/L or >145 mmol/L, and/or Serum Potassium <3.5 mmol/L or >5.5mmol/L at Follow-up Week 12
The secondary safety outcome is the proportion of participants with serum sodium \<135mmol/L or \>145 mmol/L, and/or serum potassium \<3.5 mmol/L or \>5.5mmol/L at follow-up Week 12.
Time frame: Week 12
Percentage of Participants With Serum Sodium <135 mmol/L or >145 mmol/L, and/or Serum Potassium <3.5 mmol/L or >5.5 mmol/L at Week 6
The secondary safety outcome is proportion of participants with serum sodium \<135 mmol/L or \>145 mmol/L, and/or serum potassium \<3.5 mmol/L or \>5.5 mmol/L at follow-up Week 6.
Time frame: Week 6
Percentage of Participants With Orthostatic Hypotension at Week 6
The secondary safety outcome is the proportion of participants with orthostatic hypotension at follow-up Week 6.
Time frame: Week 6
Percentage of Participants With Orthostatic Hypotension at Week 12
The secondary safety outcome is the proportion of participants with orthostatic hypotension at follow-up Week 12.
Time frame: Week 12
Percentage of Participants With Orthostatic Hypertension at Week 6
The secondary safety outcome is the proportion of participants with orthostatic hypertension at follow-up Week 6.
Time frame: Week 6
Percentage of Participants With Orthostatic Hypertension at Week 12
The secondary safety outcome is the proportion of participants with orthostatic hypertension at follow-up Week 12.
Time frame: Week 12
This trial was conducted at 83 study centers across 7 countries (Australia \[6\], Czech Republic \[2\], Great Britain \[25\], New Zealand \[2\], Poland \[9\], Sri Lanka \[14\], and USA \[25\]).
| Milestone | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Started | 2244 | 0 | 0 | 0 |
| Completed | 1385 | 0 | 0 | 0 |
| Not completed | 859 | 0 | 0 | 0 |
| Milestone | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Started | 551 | 282 | 276 | 276 |
| Completed | 527 | 273 | 259 | 259 |
| Not completed | 24 | 9 | 17 | 17 |
The primary outcome measure is difference in change in average home SBP for GMRx2 vs each dual combination evaluated from randomization to Week 12. The change in home SBP from randomization for all treatment arms was measured using least squares (LS) mean change. The pairwise comparisons between GMRx2 and dual treatments in change in home SBP were estimated using LS means difference and are described in the statistical analysis.
| mmHg | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Difference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 12 | -4.0 ± 0.45 | 1.4 ± 0.60 | -1.5 ± 0.51 | 0.4 ± 0.62 |
Difference in change in average clinic SBP for GMRx2 vs each dual combination was evaluated from randomization to Week 12.
| mmHg | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Difference in Change in Clinic Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 12 | -5.5 ± 0.55 | 0.1 ± 0.85 | -1.2 ± 1.02 | 0.9 ± 0.86 |
Difference in change in average clinic SBP for GMRx2 vs each dual combination was evaluated from randomization to Week 6.
| mmHg | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Difference in Change in Clinic Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 6 | -0.8 ± 0.50 | 4.2 ± 0.88 | 2.7 ± 0.96 | 4.5 ± 1.02 |
Difference in change in average clinic DBP for GMRx2 vs each dual combination was evaluated from randomization to Week 12.
| mmHg | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Difference in Change in Clinic Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 12 | -3.4 ± 0.42 | 0.4 ± 0.52 | 0.2 ± 0.56 | 1.1 ± 0.61 |
Difference in change in average clinic DBP for GMRx2 vs each dual combination was evaluated from randomization to Week 6.
| mmHg | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Difference in Change in Clinic Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 6 | -0.7 ± 0.38 | 1.7 ± 0.57 | 1.6 ± 0.57 | 3.1 ± 0.57 |
The percentage of participants achieving averaged clinic SBP \<140 mmHg and DBP \<90 mmHg at Week 12 was evaluated.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <140 and Diastolic Blood Pressure (DBP) <90 mmHg at Week 12 | 407 | 173 | 167 | 146 |
The percentage of participants achieving averaged clinic SBP \<140 mmHg and DBP \<80 mmHg at Week 6 was evaluated.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <140 and Diastolic Blood Pressure (DBP) <90 mmHg at Week 6 | 346 | 148 | 151 | 122 |
The percentage of participants achieving averaged clinic SBP \<130 mmHg and DBP \<80 mmHg at Week 12 was evaluated.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 12 | 218 | 65 | 76 | 59 |
The percentage of participants achieving averaged clinic SBP \<130 mmHg and DBP \<80 mmHg at Week 6 was evaluated.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 6 | 167 | 56 | 59 | 50 |
Difference in change in average home SBP for GMRx2 vs each dual combination was evaluated from randomization to Week 6.
| mmHg | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Difference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 6 | -0.9 ± 0.40 | 5.2 ± 0.57 | 2.1 ± 0.49 | 4.2 ± 0.56 |
Difference in change in average home DBP for GMRx2 vs each dual combination was evaluated from randomization to Week 12.
| mmHg | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Difference in Change in Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 12 | -2.9 ± 0.28 | 0.5 ± 0.32 | -0.8 ± 0.35 | 0.7 ± 0.45 |
Difference in change in average home DBP for GMRx2 vs each dual combination was evaluated from randomization to Week 6.
| mmHg | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Difference in Change in Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 6 | -0.7 ± 0.29 | 2.5 ± 0.39 | 1.3 ± 0.40 | 2.5 ± 0.41 |
Difference in change in trough home SBP for GMRx2 vs each dual combination was evaluated from randomization to Week 12. Trough values were measured before morning dose of the study medication.
| mmHg | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Difference in Change in Trough Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 12 | -4.0 ± 0.48 | 1.6 ± 0.59 | -2.1 ± 0.58 | -0.2 ± 0.63 |
Difference in change in trough home SBP for GMRx2 vs each dual combination was evaluated from randomization to Week 6. Trough values were measured before morning dose of the study medication.
| mmHg | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Difference in Change in Trough Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 6 | -0.9 ± 0.41 | 5.3 ± 0.66 | 1.8 ± 0.61 | 3.5 ± 0.57 |
The percentage of participants achieving averaged home SBP \<135 mmHg and DBP \<85 mmHg at week 12 was calculated.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <135 and Diastolic Blood Pressure (DBP) <85 mmHg at Week 12 | 398 | 162 | 176 | 155 |
The percentage of participants achieving averaged home SBP \<135 mmHg and DBP \<85 mmHg at Week 6 was evaluated.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <135 and Diastolic Blood Pressure (DBP) <85 mmHg at Week 6 | 346 | 126 | 155 | 123 |
The percentage of participants achieving averaged home SBP \<130 mmHg and DBP \<80 mmHg at Week 12 was evaluated.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 12 | 308 | 109 | 121 | 91 |
The percentage of participants achieving averaged home SBP \<130 mmHg and DBP \<80 mmHg at Week 6 was evaluated.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 6 | 247 | 74 | 90 | 79 |
The primary safety outcome is the proportion of participants who discontinued trial medication due to an AE or SAE from randomization to follow-up at Week 12.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants Discontinued Trial Medication Due to Adverse Event (AE)/Serious Adverse Event (SAE) From Randomization to Week 12 | 11 | 3 | 4 | 4 |
The secondary safety outcome is the proportion of participants who discontinued trial medication due to AE/SAE from randomization to follow-up at Week 6.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants Discontinued Trial Medication Due to Adverse Event (AE)/Serious Adverse Event (SAE) From Randomization to Week 6 | 5 | 3 | 1 | 3 |
The secondary safety outcome is the proportion of participants with at least one SAE from randomization to follow-up at Week 12.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants With a Serious Adverse Event (SAE) From Randomization to Week 12 | 17 | 6 | 7 | 6 |
The secondary safety outcome is the proportion of participants with at least one SAE from randomization to follow-up at Week 6.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants With Serious Adverse Event (SAE) From Randomization to Week 6 | 12 | 4 | 4 | 6 |
The secondary safety outcome is the proportion of participants who experienced at least one symptomatic hypotension episode from randomization to follow-up at Week 12.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants With Symptomatic Hypotension From Randomization to Week 12 | 32 | 5 | 11 | 4 |
The secondary safety outcome is the proportion of participants who experienced at least one symptomatic hypotension episode from randomization to follow-up at Week 6.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants With Symptomatic Hypotension From Randomization to Week 6 | 15 | 3 | 1 | 2 |
The secondary safety outcome is the proportion of participants with serum sodium \<135 mmol/L at follow-up Week 12.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants With Serum Sodium Concentration Below 135 mmol/l at Week 12 | 40 | 9 | 19 | 10 |
The secondary safety outcome is the proportion of participants with serum sodium \<135 mmol/L at follow-up Week 6.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants With Serum Sodium Concentration Below 135 mmol/l at Week 6 | 26 | 6 | 8 | 11 |
The secondary safety outcome is the proportion of participants with serum sodium \>145 mmol/L at follow-up Week 12.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants With Serum Sodium Concentration Above 145 mmol/l at Week 12 | 29 | 15 | 16 | 13 |
The secondary safety outcome is the proportion of participants with serum sodium \>145 mmol/L at follow-up Week 6.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants With Serum Sodium Concentration Above 145 mmol/l at Week 6 | 26 | 14 | 8 | 15 |
The secondary safety outcome is the proportion of participants with serum potassium concentration \<3.5 mmol/L at follow-up Week 12.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants With Serum Potassium Concentration Below 3.5 mmol/l at Week 12 | 37 | 0 | 13 | 35 |
The secondary safety outcome is the proportion of participants with serum potassium concentration below 3.5 mmol/l at follow-up Week 6.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants With Serum Potassium Concentration Below 3.5 mmol/l at Week 6 | 27 | 5 | 10 | 21 |
The secondary safety outcome is proportion of participants with serum potassium concentration \>5.5 mmol/l at follow-up Week 12.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants With Serum Potassium Concentration Above 5.5 mmol/l at Week 12 | 5 | 0 | 0 | 1 |
The secondary safety outcome is proportion of participants with serum potassium concentration \>5.5 mmol/L at follow-up Week 6.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants With Serum Potassium Concentration Above 5.5 mmol/l at Week 6 | 2 | 1 | 1 | 0 |
The secondary safety outcome was the proportion of participants with an eGFR drop of over 30% from randomization to follow-up at Week 12.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants With Estimated Glomerular Filtration Rate (eGFR) Drop of Over 30% From Randomization to Week 12 | 8 | 3 | 1 | 1 |
The secondary safety outcome is the proportion of participants with an eGFR drop of over 30% from randomization to follow-up at Week 6.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants With Estimated Glomerular Filtration Rate (eGFR) Drop of Over 30% From Randomization to Week 6 | 5 | 3 | 4 | 3 |
The secondary safety outcome is the proportion of participants with serum sodium \<135mmol/L or \>145 mmol/L, and/or serum potassium \<3.5 mmol/L or \>5.5mmol/L at follow-up Week 12.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants With Serum Sodium <135mmol/L or >145 mmol/L, and/or Serum Potassium <3.5 mmol/L or >5.5mmol/L at Follow-up Week 12 | 105 | 24 | 44 | 57 |
The secondary safety outcome is proportion of participants with serum sodium \<135 mmol/L or \>145 mmol/L, and/or serum potassium \<3.5 mmol/L or \>5.5 mmol/L at follow-up Week 6.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants With Serum Sodium <135 mmol/L or >145 mmol/L, and/or Serum Potassium <3.5 mmol/L or >5.5 mmol/L at Week 6 | 79 | 25 | 26 | 44 |
The secondary safety outcome is the proportion of participants with orthostatic hypotension at follow-up Week 6.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants With Orthostatic Hypotension at Week 6 | 27 | 14 | 20 | 15 |
The secondary safety outcome is the proportion of participants with orthostatic hypotension at follow-up Week 12.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants With Orthostatic Hypotension at Week 12 | 28 | 14 | 21 | 20 |
The secondary safety outcome is the proportion of participants with orthostatic hypertension at follow-up Week 6.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants With Orthostatic Hypertension at Week 6 | 119 | 69 | 57 | 66 |
The secondary safety outcome is the proportion of participants with orthostatic hypertension at follow-up Week 12.
| Participants | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|
| Percentage of Participants With Orthostatic Hypertension at Week 12 | 112 | 57 | 66 | 57 |
Collected over 16 weeks. Non-serious events are listed at a 0.2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Not Randomized | 0/859 (0%) | 15/859 (1.7%) | 136/859 (15.8%) |
| GMRx2 | 0/551 (0%) | 22/551 (4%) | 306/551 (55.5%) |
| Dual - TA | 0/282 (0%) | 11/282 (3.9%) | 139/282 (49.3%) |
| Dual - TI | 0/276 (0%) | 14/276 (5.1%) | 142/276 (51.4%) |
| Dual - AI | 0/276 (0%) | 8/276 (2.9%) | 136/276 (49.3%) |
| Event | Not Randomized | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|---|
| COVID-19Infections and infestations | 9/859 | 14/551 | 6/282 | 12/276 | 7/276 |
| Blood uric acid increasedInvestigations | 0/859 | 0/551 | 0/282 | 1/276 | 0/276 |
| Non-cardiac chest painGeneral disorders | 0/859 | 0/551 | 0/282 | 1/276 | 0/276 |
| Acute myocardial infarctionCardiac disorders | 0/859 | 0/551 | 0/282 | 1/276 | 0/276 |
| Lower respiratory tract infectionInfections and infestations | 0/859 | 0/551 | 0/282 | 1/276 | 0/276 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/859 | 0/551 | 0/282 | 1/276 | 0/276 |
| Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders | 0/859 | 0/551 | 0/282 | 1/276 | 0/276 |
| BursitisMusculoskeletal and connective tissue disorders | 0/859 | 0/551 | 0/282 | 1/276 | 0/276 |
| Cervical radiculopathyNervous system disorders | 0/859 | 0/551 | 0/282 | 0/276 | 1/276 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/859 | 0/551 | 0/282 | 0/276 | 1/276 |
| Event | Not Randomized | GMRx2 | Dual - TA | Dual - TI | Dual - AI |
|---|---|---|---|---|---|
| Blood glucose increasedInvestigations | 0/859 | 42/551 | 15/282 | 19/276 | 26/276 |
| Blood uric acid increasedInvestigations | 0/859 | 37/551 | 9/282 | 19/276 | 23/276 |
| HypokalemiaMetabolism and nutrition disorders | 10/859 | 28/551 | 6/282 | 8/276 | 20/276 |
| Blood potassium decreasedInvestigations | 0/859 | 14/551 | 2/282 | 8/276 | 17/276 |
| Blood cholesterol increasedInvestigations | 0/859 | 22/551 | 17/282 | 9/276 | 4/276 |
| HyponatremiaMetabolism and nutrition disorders | 19/859 | 28/551 | 12/282 | 14/276 | 16/276 |
| HeadacheNervous system disorders | 14/859 | 30/551 | 10/282 | 13/276 | 9/276 |
| Glomerular filtration rate decreasedInvestigations | 10/859 | 20/551 | 9/282 | 15/276 | 14/276 |
| Blood creatinine increasedInvestigations | 0/859 | 28/551 | 8/282 | 12/276 | 4/276 |
| DizzinessNervous system disorders | 22/859 | 28/551 | 10/282 | 4/276 | 3/276 |
| Age, Continuous(Years) | GMRx2 | Dual - TA | Dual - TI | Dual - AI | Total |
|---|---|---|---|---|---|
| Mean | 59.1 ± 11.28 | 58.7 ± 11.41 | 59.2 ± 10.29 | 58.9 ± 11.32 | 59.0 ± 11.12 |
| Sex: Female, Male(Participants) | GMRx2 | Dual - TA | Dual - TI | Dual - AI | Total |
|---|---|---|---|---|---|
| Female | 276 | 145 | 143 | 148 | 712 |
| Male | 275 | 137 | 133 | 128 | 673 |
| Ethnicity (NIH/OMB)(Participants) | GMRx2 | Dual - TA | Dual - TI | Dual - AI | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 63 | 31 | 30 | 35 | 159 |
| Not Hispanic or Latino | 487 | 250 | 246 | 241 | 1224 |
| Unknown or Not Reported | 1 | 1 | 0 | 0 | 2 |
| Race (NIH/OMB)(Participants) | GMRx2 | Dual - TA | Dual - TI | Dual - AI | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 |
| Asian | 272 | 135 | 132 | 134 | 673 |
| Native Hawaiian or Other Pacific Islander | 2 | 3 | 3 | 1 | 9 |
| Black or African American | 30 | 11 | 13 | 16 | 70 |
| White | 246 | 132 | 128 | 125 | 631 |
| More than one race | 1 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | GMRx2 | Dual - TA | Dual - TI | Dual - AI | Total |
|---|---|---|---|---|---|
| New Zealand | 8 | 4 | 4 | 4 | 20 |
| United States | 83 | 44 | 42 | 49 | 218 |
| Sri Lanka | 260 | 131 | 128 | 127 | 646 |
| Czechia | 4 | 2 | 3 | 2 | 11 |
| Poland | 4 | 2 | 2 | 1 | 9 |
| United Kingdom | 138 | 73 | 72 | 68 | 351 |
| Australia | 54 | 26 | 25 | 25 | 130 |
| Body Mass Index (BMI)(Kg/m^2) | GMRx2 | Dual - TA | Dual - TI | Dual - AI | Total |
|---|---|---|---|---|---|
| Mean | 28.87 ± 5.688 | 28.68 ± 5.735 | 29.05 ± 5.686 | 28.82 ± 6.022 | 28.86 ± 5.761 |
| Weight(Kg) | GMRx2 | Dual - TA | Dual - TI | Dual - AI | Total |
|---|---|---|---|---|---|
| Mean | 79.09 ± 20.714 | 78.19 ± 19.995 | 79.38 ± 20.623 | 78.03 ± 20.859 | 78.75 ± 20.565 |
| Height(cm) | GMRx2 | Dual - TA | Dual - TI | Dual - AI | Total |
|---|---|---|---|---|---|
| Mean | 164.72 ± 11.054 | 164.47 ± 10.659 | 164.54 ± 11.566 | 163.84 ± 11.702 | 164.46 ± 11.204 |
5 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — If the sponsor receives a request for study data, then such requests will be reviewed by sponsor following completion of regulatory submissions and review, and with support from members of the GMRX2 steering committee who will advise on the scientific merit and integrity of the proposed analysis.
Ran from Jul 2021 to primary completion in Aug 2023, 25 months.
Results were first posted in Jun 2025, 1 year 9 months after primary completion.
Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 25 months is above that.
Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Telmisartan
George Medicines PTY Limited